Leerink Raises Price Target as Roivant (ROIV) Accelerates Drug Development Pipeline

Core Insights - Roivant Sciences Ltd. (NASDAQ:ROIV) is highlighted as one of the best stocks under $25 to buy, with an increased price target of $32 from Leerink Partners, maintaining an Outperform rating due to lower estimated operational expenses and anticipated profitability starting in fiscal year 2029 [1] Group 1: Company Projections - By the end of 2028, Roivant's "Next 36 Month vision" includes expectations for at least three commercial launches, four or more NDA/BLA submissions, no less than eight crucial readouts, and at least three proof-of-concept evaluations [2] - The development schedules for Roivant's primary therapeutic candidates have been advanced, including brepocitinib, with a New Drug Application filing for dermatomyositis expected in early 2026 and a potential commercial launch in early 2027 [3] Group 2: Clinical Development - The Phase III trial for brepocitinib in non-infectious uveitis has achieved full enrollment ahead of schedule, with topline results anticipated in the second half of 2026 [3] - Roivant Sciences Ltd. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing medicines and technologies, with clinical product candidates including IMVT-1402 for Graves' disease and difficult-to-treat rheumatoid arthritis [4]